Biotech China Healthcare Hong Kong Investment IPO Medicine Pharmaceutical Singapore Software Technology United States
In an interview with the South China Morning Post, METiS TechBio CEO Lai Tsai-ta likened ageing to bugs accumulating in a complex software system, arising from errors in the genetic code of human cells. Lai emphasized the potential of AI in reading, rewriting, and reversing cells to slow the ageing process. The focus could initially be on repairing immune cells like T cells, crucial as their function declines with age, increasing vulnerability to diseases including cancer. METiS TechBio, a six-year-old start-up, is leveraging AI algorithms to develop nano-delivery platforms for targeted drug delivery into specific cells and organs. Following a…
News Timeline:
Track the development of this news story across the Internet.